RT001 Granted Rare Pediatric Disease Designation for INAD, FA
source: pixabay.com

RT001 Granted Rare Pediatric Disease Designation for INAD, FA

In a press release from late February 2021, biopharmaceutical company Retrotope shared that its lead drug candidate, RT001, received Rare Pediatric Disease designation for the treatment of patients with Friedreich's…

Continue Reading RT001 Granted Rare Pediatric Disease Designation for INAD, FA
FDA Permits Retrotrope’s Phase 2/3 Study of Infantile Neuroaxonal Dystrophy Drug Candidate
source: pixabay.com

FDA Permits Retrotrope’s Phase 2/3 Study of Infantile Neuroaxonal Dystrophy Drug Candidate

According to a press release from the California-based biotechnology company Retrotrope, Inc., the Company has completed recruitment for its upcoming phase 2/3 study of RT001, an experimental drug designed for…

Continue Reading FDA Permits Retrotrope’s Phase 2/3 Study of Infantile Neuroaxonal Dystrophy Drug Candidate